ArticleAnnals of clinical and translational neurology2026
Effects of Add-On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic stroke, a major cause of mortality and long-term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA-EE), approved for hypertriglyceridemia, has anti-inflammatory and antithrombotic properties that may lessen ischemic damage.
objectivesThis trial evaluates the impact of EPA-EE on functional recovery and inflammatory markers in patients with acute ischemic stroke.
methodsIn a blinded, randomized controlled trial (RCT), adults (≥ 18 years) with acute ischemic stroke were assigned to receive either 2000 mg/day EPA-EE (EPA group) or a matched placebo alongside standard treatment for 12 weeks. Functional outcomes were measured using the modified Rankin scale (mRS) and national institutes of health stroke scale (NIHSS), while inflammatory biomarkers, interleukin-6 (IL-6) and C-reactive protein (CRP), were assessed at baseline and at the 7th day.
resultsOf 178 patients screened, 90 were randomized, and 80 completed the 12-week intervention. The EPA group showed significantly greater functional improvement, with mean mRS score reductions of 2.18 ± 0.61 compared to 1.38 ± 0.66 in the placebo group (p = 0.001) and NIHSS score reductions of 5.00 ± 1.83 versus 3.38 ± 1.38 (p = 0.001). IL-6 levels decreased by 6.32 ± 5.69 pg/mL in the EPA group compared to 2.95 ± 4.11 pg/mL in the placebo group (p = 0.003). Changes in CRP levels were not statistically significant (p = 0.142). EPA-EE at 2000 mg/day was well tolerated, with no serious adverse events reported.
conclusionEPA-EE administration significantly improves functional outcomes and reduces IL-6 levels in patients with acute ischemic stroke, suggesting its potential as an effective add-on therapy.
trial registrationCLINICALTRIALS. GOV IDENTIFIER: IRCT20170608034390N15.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.